Medios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidating patient-specific manufacturing at its remaining locations across Germany. The company announced that production has already been relocated, and supplies to pharmacies and hospitals are guaranteed. Aschaffenburg most recently accounted for approximately 10% of the production volume of the Medios Group's German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation.
The business of patient-specific formulations is under sustained margin pressure – particularly due to price regulatory adjustments – which the company is now countering with measures to increase efficiency. In Germany, Medios operates a network of six GMP manufacturing facilities for patient-specific therapies. GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management. The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Against this backdrop, continued economic operation was no longer feasible. Structural renovation work currently required at the site has accelerated the implementation of this decision. The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability.
Thomas Meier, CEO of Medios AG, stated: “With a view to ensuring a reliable supply for our customers and maintaining capacity utilization at all sites, we are now optimizing our successful regional presence strategy and consistently developing it further. With Mannheim and Stuttgart, we have two high-performing Medios sites in southern Germany, ensuring that a reliable supply is maintained.”
Important events for the Medios Group in the 2026 financial year include: August 12 Half-Year Financial Report 2026; September 21 to 23 Berenberg and Goldman Sachs 15th German Corporate Conference – Munich; September 28/29 Medios Capital Markets Day, Breda; and November 10 Quarterly Statement as of September 30, 2026.
Medios AG is a leading provider of Specialty Pharma in Europe. The company supports key partners in the supply chain with innovative solutions and intelligent services, focusing on pioneering individualized medicine. Medios AG is Germany's first listed specialty pharmaceutical company, listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index. For more information, visit Medios Group.
This closure highlights the challenges faced by specialty pharmaceutical manufacturers in Germany due to regulatory price pressures, and Medios' strategic response to maintain profitability while ensuring supply continuity. The company's optimization of its manufacturing network is a key step in its Operational Excellence Program.
